Treatment of Comorbid Anxiety and Alcohol Use Disorder

Initial Assessment and Diagnosis

The American Association for the Study of Liver Diseases recommends using the AUDIT questionnaire as the gold standard screening tool to assess alcohol use severity, with scores ≥8 for men or ≥4 for women indicating positive screening 2, 1
The National Institute on Alcohol Abuse and Alcoholism suggests screening for specific anxiety disorders, including panic disorder, social phobia, obsessive-compulsive disorder, generalized anxiety disorder, and PTSD, as these commonly co-occur with alcohol use disorder 2
The American Psychiatric Association recommends assessing for psychiatric comorbidities systematically, as up to 50% of patients with alcohol use disorder have concurrent psychiatric conditions 2
The Society for Research on Nicotine and Tobacco recommends screening for nicotine dependence, as up to 80% of patients with alcohol use disorder are heavy smokers requiring intensive cessation support 2

The American College of Physicians recommends brief motivational interventions using the FRAMES model, which reduces morbidity and mortality related to drinking 3, 1
The National Institute on Alcohol Abuse and Alcoholism suggests implementing multicontact behavioral counseling rather than single sessions, as this demonstrates superior outcomes 1
The American Medical Association recommends actively encouraging engagement with Alcoholics Anonymous, which has high effectiveness for maintaining abstinence with reported 50% abstinence rates at one year 1, 4
The American Psychological Association recommends adding cognitive-behavioral therapy focused on teaching alternative methods to alleviate anxiety without alcohol, including relaxation therapy and assertiveness training 5, 3

The American College of Clinical Pharmacology recommends naltrexone 50mg daily as the primary pharmacotherapy for patients without advanced liver disease, as it reduces relapse to heavy drinking and drinking frequency by reducing heavy drinking days up to 30% 1
The European Association for the Study of the Liver recommends using baclofen instead of naltrexone or acamprosate for patients with advanced liver disease, as it is safe and effective for preventing alcohol relapse in advanced alcoholic liver disease 5, 3, 1
The American Gastroenterological Association recommends avoiding SSRIs due to lack of evidence for improving outcomes in comorbid anxiety-alcohol use disorder and potential to worsen alcohol-related outcomes 1, 6

The American Society of Addiction Medicine recommends a minimum treatment duration of 12-14 weeks of combined pharmacotherapy and psychotherapy 6
The National Institute on Alcohol Abuse and Alcoholism suggests follow-up every 1-3 months to assess progress, as relapse rates reach 50% at one year 4, 6
The American College of Physicians recommends monitoring for withdrawal symptoms if reducing alcohol, occurring in up to 50% of patients with severe dependence 4
The American Medical Association recommends providing oral thiamine to all patients, with parenteral thiamine for high-risk individuals 1